These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 7706734)

  • 1. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
    J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
    Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
    Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
    J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
    Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
    J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.
    Kobayashi H; Lu J; Celis E
    Cancer Res; 2001 Oct; 61(20):7577-84. PubMed ID: 11606397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
    J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
    Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
    Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
    Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.